Navigation Links
Endo Pharmaceuticals Holdings Inc. Announces Pricing of Private Offering of Senior Notes
Date:11/18/2010

ents to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. You should understand that these statements are not guarantees of performance or results and are preliminary in nature. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties.

You should consider the areas of risk described under the heading "Forward-Looking Statements" and "Risk Factors" in Endo's periodic reports filed with the Securities and Exchange Commission under the Exchange Act and those risk factors included as "Item 1A. Risk Factors" in Endo's Quarterly Report on Form 10-Q for the three months ended September 30, 2010, as updated by the risk factors set forth in any subsequent filing by Endo with the Securities and Exchange Commission, in connection with any forward-looking statements that may be made by Endo generally. Except for ongoing obligations to disclose material information under the federal securities laws, Endo undertakes no obligation to release publicly any updates or revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events unless required by law.


'/>"/>
SOURCE Endo Pharmaceuticals Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care protoc ... improving outcomes and the cost of healthcare delivery   ... PHIA) today announced its presence at  ESC Congress 2015 , where ... Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect people ...
(Date:8/27/2015)... Va. , Aug. 27, 2015  The ... the Food and Drug Administration,s (FDA,s) draft guidance ... reference products and biosimilars, to bear a nonproprietary ... AMCP has been seeking a decision from the ... 18 diverse health care stakeholders urging the agency ...
(Date:8/27/2015)... DURECT Corporation (Nasdaq: DRRX ) announced ... upcoming healthcare conferences.  , James ... the Rodman & Renshaw Investment Conference on Thursday, September ... being held at the St. Regis Hotel in ... webcast of the presentation will be available by accessing ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2DURECT to Participate in Upcoming Healthcare Conferences 2
... FOLD ) today announced that John F. Crowley ... Chairman in order to devote more time to interests related ... role as Executive Chairman, Mr. Crowley will continue to perform ... will advise the current Amicus management team on corporate strategy ...
... The board of directors of Eli Lilly and Company (NYSE: ... second quarter of 2011 of $0.49 a share on outstanding ... 10, 2011 to shareholders of record at the close of ... innovation-driven corporation, is developing a growing portfolio of pharmaceutical products ...
Cached Medicine Technology:Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman 2
(Date:8/28/2015)... , ... August 28, 2015 , ... ... grams of high grade protein with zero fat, carbs, sugar, gluten, lactose or ... named a finalist for the 2015 SupplySide CPG Editor’s Choice Awards. , Five ...
(Date:8/28/2015)... ... August 28, 2015 , ... Medical Solutions, one of the nation’s largest ... Work in Healthcare by Modern Healthcare and will be honored at an awards ... eighth year, the Best Places to Work in Healthcare program recognizes outstanding employers in ...
(Date:8/28/2015)... ... 2015 , ... SmartPractice Calendars afford dental offices ... contact information and logos, Calendars stand alone as functional brand-building giveaways ... mailings, thank you and welcome communications, and to complement statements and invoices. 2016 ...
(Date:8/28/2015)... ... August 28, 2015 , ... SharkNinja, an innovative leader in ... Emmy-nominated actress, Sofia Vergara, and unveil the Ninja® brand’s new coffee machine, ... delivers a variety of sizes and styles while achieving the perfect brew richness ...
(Date:8/28/2015)... Washington, DC (PRWEB) , ... ... ... Atlantic Information Services, Inc.’s (AIS) Medicare-Medicaid Dual Eligibles Database have added comprehensive ... newest CMS-backed alignment demonstration approved for a December 2015 launch; and Idaho’s ...
Breaking Medicine News(10 mins):Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2
... microscope, scientists have tried to visualize smaller and smaller structures ... bacteria and viruses. Now, researchers at the National Institute ... the National Institutes of Health, have developed a new way ... before. Their findings are reported in the Jan. 13 ...
... (HealthDay News) -- The chemotherapy used to treat a form ... the return of the disease within years, a new study ... who thought chemotherapy drugs could disrupt DNA through mutations and ... medications. "Chemotherapy drugs are absolutely necessary to get ...
... Jefferson,s Kimmel Cancer Center has started a ... cancer chemotherapy drug to extend survival, Cabazitaxel, in ... approach could improve disease control and eventually survival ... single-center, open-label, non-randomized Phase I study ...
... Using two cell surface markers found to be ... researchers at Moffitt Cancer Center, working with colleagues ... imaging probes that can non-invasively detect breast cancer ... breast cancer patients invasive and unreliable sentinel lymph ...
... women are scarce leads men to become impulsive, save less, ... of Minnesota,s Carlson School of Management. "What we see ... become more competitive. They compete more for access to mates," ... Carlson School and lead author of the study. "How do ...
... language are quicker at recognizing and interpreting body language than ... Davis and UC Irvine. The work suggests that deaf ... visual traits in the actions of others, an ability that ... screening. "There are a lot of anecdotes about deaf ...
Cached Medicine News:Health News:NIH scientists identify novel approach to view inner workings of viruses 2Health News:DNA Damage From Chemo May Help Spur Leukemia's Return 2Health News:Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival 2Health News:Researchers find new, noninvasive way to identify lymph node metastasis 2Health News:A scarcity of women leads men to spend more, save less 2Health News:A scarcity of women leads men to spend more, save less 3Health News:Deaf sign language users pick up faster on body language 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: